Marie Høyer Lundh1, Claudia Lampic2, Karin Nordin3, Johan Ahlgren4, Leif Bergkvist5, Mats Lambe6, Anders Berglund7, Birgitta Johansson8. 1. Regional Cancer Centre, Uppsala University Hospital, SE-751 85 Uppsala, Sweden; Department of Public Health and Caring Sciences, Uppsala University, Box 564, SE-751 22 Uppsala, Sweden. Electronic address: marie.hoyer.lundh@pubcare.uu.se. 2. Department of Public Health and Caring Sciences, Uppsala University, Box 564, SE-751 22 Uppsala, Sweden; Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels allé 23, 23300, SE-141 83 Huddinge, Sweden. 3. Department of Public Health and Caring Sciences, Uppsala University, Box 564, SE-751 22 Uppsala, Sweden; Department of Global Public Health and Primary Care, University of Bergen, Postboks 7804, NO-5020 Bergen, Norway. 4. Department of Oncology, Örebro University Hospital, SE-70185 Örebro, Sweden; Centre for Research and Development, Uppsala University, County of Gävleborg, SE-801 88 Gävle, Sweden. 5. Department of Surgery and Centre for Clinical Research, Uppsala University, Västmanland County Hospital, SE-721 89 Västerås, Sweden. 6. Regional Cancer Centre, Uppsala University Hospital, SE-751 85 Uppsala, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden. 7. Regional Cancer Centre, Uppsala University Hospital, SE-751 85 Uppsala, Sweden; Department of Surgical Sciences, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden. 8. Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Abstract
PURPOSE: To compare sickness absence and disability pension in a population-based cohort of women with breast cancer (n = 463) from 1 year pre-diagnosis until 3 years post-diagnosis with a matched control group (n = 2310), and to investigate predictors of sickness absence during the 2nd and 3rd year post-diagnosis. RESULTS: Following breast cancer, the proportion of disease-free women with sickness absence decreased post-diagnosis (1st-3rd year; 78%-31%-19%), but did not reach the pre-diagnostic level (14%; P < 0.05). Post-diagnosis, patients were more likely than controls to be sickness absent (1st-3rd year; P < 0.001). No between-group differences were observed for disability pension post-diagnosis (P > 0.05). Among patients, chemotherapy, baseline fatigue and pre-diagnosis sick days predicted sickness absence during the 2nd, 3rd, and 2nd and 3rd year post-diagnosis, respectively (P < 0.05). CONCLUSIONS: Breast cancer is associated with increased sickness absence 3 years post-diagnosis. In a clinical setting, prevention and treatment of side effects are important in reducing long-term consequences.
PURPOSE: To compare sickness absence and disability pension in a population-based cohort of women with breast cancer (n = 463) from 1 year pre-diagnosis until 3 years post-diagnosis with a matched control group (n = 2310), and to investigate predictors of sickness absence during the 2nd and 3rd year post-diagnosis. RESULTS: Following breast cancer, the proportion of disease-free women with sickness absence decreased post-diagnosis (1st-3rd year; 78%-31%-19%), but did not reach the pre-diagnostic level (14%; P < 0.05). Post-diagnosis, patients were more likely than controls to be sickness absent (1st-3rd year; P < 0.001). No between-group differences were observed for disability pension post-diagnosis (P > 0.05). Among patients, chemotherapy, baseline fatigue and pre-diagnosis sick days predicted sickness absence during the 2nd, 3rd, and 2nd and 3rd year post-diagnosis, respectively (P < 0.05). CONCLUSIONS:Breast cancer is associated with increased sickness absence 3 years post-diagnosis. In a clinical setting, prevention and treatment of side effects are important in reducing long-term consequences.
Authors: Li Wang; Brian Y Hong; Sean A Kennedy; Yaping Chang; Chris J Hong; Samantha Craigie; Henry Y Kwon; Beatriz Romerosa; Rachel J Couban; Susan Reid; James S Khan; Michael McGillion; Victoria Blinder; Jason W Busse Journal: J Clin Oncol Date: 2018-05-14 Impact factor: 44.544
Authors: Laura Schärfe Jensen; Charlotte Overgaard; Henrik Bøggild; Jens Peter Garne; Thomas Lund; Kim Overvad; Kirsten Fonager Journal: BMC Public Health Date: 2017-10-30 Impact factor: 3.295
Authors: Anna Plym; Hannah Bower; Irma Fredriksson; Lars Holmberg; Paul C Lambert; Mats Lambe Journal: Br J Cancer Date: 2018-01-23 Impact factor: 7.640
Authors: Alv A Dahl; Anne Gry Bentzen; Sophie D Fosså; Siri Lothe Hess; Rita Steen; Cecilie E Kiserud Journal: J Cancer Surviv Date: 2020-04-11 Impact factor: 4.442
Authors: Anna Plym; Anna L V Johansson; Hannah Bower; Anna-Karin Wennstig; Irma Fredriksson; Johan Ahlgren; Mats Lambe Journal: Breast Cancer Res Treat Date: 2020-06-06 Impact factor: 4.872
Authors: Rimke Bijker; Saskia F A Duijts; Sherzel N Smith; Renée de Wildt-Liesveld; Johannes R Anema; Barbara J Regeer Journal: J Occup Rehabil Date: 2018-09
Authors: Pia K Kvillemo; Lingjing Chen; Matteo Bottai; Paolo Frumento; Gino Almondo; Ellenor Mittendorfer-Rutz; Emilie Friberg; Kristina A E Alexanderson Journal: BMC Public Health Date: 2021-04-09 Impact factor: 3.295
Authors: Renske Altena; Sofie A M Gernaat; Ulla Wilking; Narsis A Kiani; Aina Johnsson; Elham Hedayati Journal: Eur J Cancer Care (Engl) Date: 2022-05-27 Impact factor: 2.328